Insights into myalgic encephalomyelitis/chronic fatigue syndrome phenotypes through comprehensive metabolomics
Dorottya Nagy-Szakal, Dinesh K Barupal, Bohyun Lee, Xiaoyu Che, Brent L Williams, Ellie J R Kahn, Joy E Ukaigwe, Lucinda Bateman, Nancy G Klimas, Anthony L Komaroff, Susan Levine, Jose G Montoya, Daniel L Peterson, Bruce Levin, Mady Hornig, Oliver Fiehn, W Ian Lipkin, Dorottya Nagy-Szakal, Dinesh K Barupal, Bohyun Lee, Xiaoyu Che, Brent L Williams, Ellie J R Kahn, Joy E Ukaigwe, Lucinda Bateman, Nancy G Klimas, Anthony L Komaroff, Susan Levine, Jose G Montoya, Daniel L Peterson, Bruce Levin, Mady Hornig, Oliver Fiehn, W Ian Lipkin
Abstract
The pathogenesis of ME/CFS, a disease characterized by fatigue, cognitive dysfunction, sleep disturbances, orthostatic intolerance, fever, irritable bowel syndrome (IBS), and lymphadenopathy, is poorly understood. We report biomarker discovery and topological analysis of plasma metabolomic, fecal bacterial metagenomic, and clinical data from 50 ME/CFS patients and 50 healthy controls. We confirm reports of altered plasma levels of choline, carnitine and complex lipid metabolites and demonstrate that patients with ME/CFS and IBS have increased plasma levels of ceramide. Integration of fecal metagenomic and plasma metabolomic data resulted in a stronger predictive model of ME/CFS (cross-validated AUC = 0.836) than either metagenomic (cross-validated AUC = 0.745) or metabolomic (cross-validated AUC = 0.820) analysis alone. Our findings may provide insights into the pathogenesis of ME/CFS and its subtypes and suggest pathways for the development of diagnostic and therapeutic strategies.
Conflict of interest statement
The authors declare no competing interests.
Figures
References
- Institute of Medicine, I. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: Redefining an illness. Washington, DC: The National Academies Press. (2015).
- Aaron LA, et al. Comorbid clinical conditions in chronic fatigue: a co-twin control study. J Gen Intern Med. 2001;16:24–31.
- Hausteiner-Wiehle C, Henningsen P. Irritable bowel syndrome: relations with functional, mental, and somatoform disorders. World J Gastroenterol. 2014;20:6024–6030. doi: 10.3748/wjg.v20.i20.6024.
- Kim SE, Chang L. Overlap between functional GI disorders and other functional syndromes: what are the underlying mechanisms? Neurogastroenterol Motil. 2012;24:895–913. doi: 10.1111/j.1365-2982.2012.01993.x.
- Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71–80.
- Endo Y, Shoji T, Fukudo S. Epidemiology of irritable bowel syndrome. Ann Gastroenterol. 2015;28:158–159.
- Armstrong CW, McGregor NR, Butt HL, Gooley PR. Metabolism in chronic fatigue syndrome. Adv Clin Chem. 2014;66:121–172. doi: 10.1016/B978-0-12-801401-1.00005-0.
- Naviaux RK, et al. Metabolic features of chronic fatigue syndrome. Proc Natl Acad Sci USA. 2016;113:E5472–5480. doi: 10.1073/pnas.1607571113.
- Yamano E, et al. Index markers of chronic fatigue syndrome with dysfunction of TCA and urea cycles. Sci Rep. 2016;6:34990. doi: 10.1038/srep34990.
- Fluge, O. et al. Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. Jci Insight1 (2016).
- Armstrong CW, McGregor NR, Lewis DP, Butt HL, Gooley PR. Metabolic profiling reveals anomalous energy metabolism and oxidative stress pathways in chronic fatigue syndrome patients. Metabolomics. 2015;11:1626–1639. doi: 10.1007/s11306-015-0816-5.
- Armstrong CW, et al. NMR metabolic profiling of serum identifies amino acid disturbances in chronic fatigue syndrome. Clin Chim Acta. 2012;413:1525–1531. doi: 10.1016/j.cca.2012.06.022.
- Germain A, Ruppert D, Levine SM, Hanson MR. Metabolic profiling of a myalgic encephalomyelitis/chronic fatigue syndrome discovery cohort reveals disturbances in fatty acid and lipid metabolism. Mol Biosyst. 2017;13:371–379. doi: 10.1039/C6MB00600K.
- Nagy-Szakal D, et al. Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome. 2017;5:44. doi: 10.1186/s40168-017-0261-y.
- Fukuda K, et al. The Chronic Fatigue Syndrome - a Comprehensive Approach to Its Definition and Study. Annals of Internal Medicine. 1994;121:953–959. doi: 10.7326/0003-4819-121-12-199412150-00009.
- Carruthers BM. Definitions and aetiology of myalgic encephalomyelitis: how the Canadian consensus clinical definition of myalgic encephalomyelitis works. J Clin Pathol. 2007;60:117–119. doi: 10.1136/jcp.2006.042754.
- Breiman L. Random Forests. Machine Learning. 2001;45:5–32. doi: 10.1023/A:1010933404324.
- Barupal DK, et al. MetaMapp: mapping and visualizing metabolomic data by integrating information from biochemical pathways and chemical and mass spectral similarity. BMC Bioinformatics. 2012;13:99. doi: 10.1186/1471-2105-13-99.
- Walker, A. et al. Sulfonolipids as novel metabolite markers of Alistipes and Odoribacter affected by high-fat diets. Sci Rep-Uk7 (2017).
- Wieland Brown LC, et al. Production of alpha-galactosylceramide by a prominent member of the human gut microbiota. PLoS Biol. 2013;11:e1001610. doi: 10.1371/journal.pbio.1001610.
- North JA, Miller AR, Wildenthal JA, Young SJ, Tabita FR. Microbial pathway for anaerobic 5′-methylthioadenosine metabolism coupled to ethylene formation. Proc Natl Acad Sci USA. 2017;114:E10455–E10464. doi: 10.1073/pnas.1711625114.
- Zhang LS, Davies SS. Microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions. Genome Med. 2016;8:46. doi: 10.1186/s13073-016-0296-x.
- Miquel, S. et al. Identification of metabolic signatures linked to anti-inflammatory effects of Faecalibacterium prausnitzii. MBio6 (2015).
- Sakamoto M, Benno Y. Reclassification of Bacteroides distasonis, Bacteroides goldsteinii and Bacteroides merdae as Parabacteroides distasonis gen. nov., comb. nov., Parabacteroides goldsteinii comb. nov and Parabacteroides merdae comb. nov. Int J Syst Evol Micr. 2006;56:1599–1605. doi: 10.1099/ijs.0.64192-0.
- Taras D, Simmering R, Collins MD, Lawson PA, Blaut M. Reclassification of Eubacterium formicigenerans Holdeman and Moore 1974 as Dorea formicigenerans gen. nov., comb. nov., and description of Dorea longicatena sp nov., isolated from human faeces. Int J Syst Evol Micr. 2002;52:423–428. doi: 10.1099/00207713-52-2-423.
- Tomic S, Brkic S, Maric D, Mikic AN. Lipid and protein oxidation in female patients with chronic fatigue syndrome. Arch Med Sci. 2012;8:886–891. doi: 10.5114/aoms.2012.31620.
- Jazvinscak Jembrek M, Hof PR, Simic G. Ceramides in Alzheimer’s Disease: Key Mediators of Neuronal Apoptosis Induced by Oxidative Stress and Abeta Accumulation. Oxid Med Cell Longev. 2015;2015:346783. doi: 10.1155/2015/346783.
- Contreras C, et al. Central ceramide-induced hypothalamic lipotoxicity and ER stress regulate energy balance. Cell Rep. 2014;9:366–377. doi: 10.1016/j.celrep.2014.08.057.
- Kajander K, et al. Elevated pro-inflammatory and lipotoxic mucosal lipids characterise irritable bowel syndrome. World J Gastroenterol. 2009;15:6068–6074. doi: 10.3748/wjg.15.6068.
- Chaurasia B, Summers SA. Ceramides - Lipotoxic Inducers of Metabolic Disorders. Trends Endocrinol Metab. 2015;26:538–550. doi: 10.1016/j.tem.2015.07.006.
- Giloteaux L, et al. Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome. 2016;4:30. doi: 10.1186/s40168-016-0171-4.
- Sakata A, et al. Inhibition of lipopolysaccharide-induced release of interleukin-8 from intestinal epithelial cells by SMA, a novel inhibitor of sphingomyelinase and its therapeutic effect on dextran sulphate sodium-induced colitis in mice. Cell Immunol. 2007;245:24–31. doi: 10.1016/j.cellimm.2007.03.005.
- Jones MG, Goodwin CS, Amjad S, Chalmers RA. Plasma and urinary carnitine and acylcarnitines in chronic fatigue syndrome. Clin Chim Acta. 2005;360:173–177. doi: 10.1016/j.cccn.2005.04.029.
- Reuter SE, Evans AM. Long-chain acylcarnitine deficiency in patients with chronic fatigue syndrome. Potential involvement of altered carnitine palmitoyltransferase-I activity. J Intern Med. 2011;270:76–84. doi: 10.1111/j.1365-2796.2010.02341.x.
- Vermeulen RC, Scholte HR. Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome. Psychosom Med. 2004;66:276–282. doi: 10.1097/01.psy.0000116249.60477.e9.
- Zhu H, et al. Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway. PLoS One. 2013;8:e68283. doi: 10.1371/journal.pone.0068283.
- Kaddurah-Daouk R, et al. Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. Transl Psychiatry. 2013;3:e223. doi: 10.1038/tp.2012.142.
- Slominski A, et al. Metabolism of serotonin to N-acetylserotonin, melatonin, and 5-methoxytryptamine in hamster skin culture. J Biol Chem. 1996;271:12281–12286. doi: 10.1074/jbc.271.21.12281.
- Yu AM, et al. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics. 2003;13:173–181. doi: 10.1097/00008571-200303000-00007.
- Yamamoto S, et al. Reduction of serotonin transporters of patients with chronic fatigue syndrome. Neuroreport. 2004;15:2571–2574. doi: 10.1097/00001756-200412030-00002.
- Klimas N, et al. Findings from a clinical and laboratory database developed for discovery of pathogenic mechanisms in myalgic encephalomyelitis/chronic fatigue syndrome. Fatigue. 2015;3:75–96.
- Alter, H. J. et al. A multicenter blinded analysis indicates no association between chronic fatigue syndrome/myalgic encephalomyelitis and either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus. MBio3 (2012).
- Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index - a New Instrument for Psychiatric Practice and Research. Psychiat Res. 1989;28:193–213. doi: 10.1016/0165-1781(89)90047-4.
- Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–483. doi: 10.1097/00005650-199206000-00002.
- Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39:315–325. doi: 10.1016/0022-3999(94)00125-O.
- Jason L, et al. The development of a revised Canadian myalgic encephalomyelitis chronic fatigue syndrome case definition. Am J Biochem Biotechnol. 2010;6:120–135. doi: 10.3844/ajbbsp.2010.120.135.
- Fahrmann JF, et al. Serum phosphatidylethanolamine levels distinguish benign from malignant solitary pulmonary nodules and represent a potential diagnostic biomarker for lung cancer. Cancer Biomark. 2016;16:609–617.
- Gaikwad NW. Ultra performance liquid chromatography-tandem mass spectrometry method for profiling of steroid metabolome in human tissue. Anal Chem. 2013;85:4951–4960. doi: 10.1021/ac400016e.
- Fahrmann J, et al. Systemic alterations in the metabolome of diabetic NOD mice delineate increased oxidative stress accompanied by reduced inflammation and hypertriglyceremia. Am J Physiol Endocrinol Metab. 2015;308:E978–989. doi: 10.1152/ajpendo.00019.2015.
- Wu Y, Li L. Sample normalization methods in quantitative metabolomics. J Chromatogr A. 2016;1430:80–95. doi: 10.1016/j.chroma.2015.12.007.
- Hua J, Xiong Z, Lowey J, Suh E, Dougherty ER. Optimal number of features as a function of sample size for various classification rules. Bioinformatics. 2005;21:1509–1515. doi: 10.1093/bioinformatics/bti171.
- Austin PC, Steyerberg EW. The number of subjects per variable required in linear regression analyses. J Clin Epidemiol. 2015;68:627–636. doi: 10.1016/j.jclinepi.2014.12.014.
- Benjamini Y, Hochberg Y. Controlling the false discovery rate—A practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289–300.
- Hinks T, et al. Multidimensional endotypes of asthma: topological data analysis of cross-sectional clinical, pathological, and immunological data. Lancet. 2015;385(Suppl 1):S42. doi: 10.1016/S0140-6736(15)60357-9.
Source: PubMed